替格瑞洛致呼吸困难的研究进展  

Research progress of ticagrelor-induced dyspnea

作　　者：黄小红[1] 陈宜锋[1] 李立[1] 黄小洪[2] 林光宇[2] 

机构地区：[1]福建医科大学附属漳州市医院药学部,福建漳州363000 [2]福建医科大学附属漳州市医院心血管内科,福建漳州363000

出　　处：《中国新药与临床杂志》2015年第8期569-572,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：替格瑞洛是一种新型口服血小板P2Y12受体拮抗剂,已成为临床急性冠状动脉综合征指南推荐的首选抗栓治疗药物之一,但替格瑞洛相关的呼吸困难比氯吡格雷更为常见,发生率在10%以上。本文通过查阅近年来替格瑞洛的临床研究相关文献,对其导致的呼吸困难研究进展进行综述,以便更好地了解这一不良反应的发生率、发生机制、预后及对策,为临床安全用药提供理论基础。Ticagrelor has become one of antithrombotic drugs recommended by clinical guidelines for acute coronary syndrome, as the novel platelet P2Y12 receptor antagonist. The incidence of ticagrelor-associated dyspnea was higher than clopidogrel, which was above than 10%. This paper summarized the progress of ticagrelor-induced dyspnea by consulting relevant literatures in recent years, in order to better understand the incidence, mechanisms, outcomes and solutions of this adverse reaction and to provide some theoretical basis for the further research of ticagrelor in clinical safe application.

关 键 词：替格瑞洛 氯吡格雷 呼吸困难 药物不良反应 

分 类 号：R973.2[医药卫生—药品]